Diligence memo · auto-generated · as of July 2, 2026
Access Bio, Inc.
Access Bio, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Access Bio, Inc. operates in Biotechnology, based in SOMERSET.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Access Bio, Inc. has raised $30M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2011-05-09.
Most recent recorded round closed around 2020-11-17.
Valuation (modeled)modeled
Provath models Access Bio, Inc. at approximately $301M (range $11M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.67× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 57 months.
Last raise 5.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 75% of Biotechnology peers (4293 compared).
Modeled value ranks above 77% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.